XBI - SPDR S&P Biotech ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
92.47
-0.26 (-0.28%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close92.73
Open92.49
Bid87.61 x 200
Ask88.21 x 200
Day's Range91.97 - 93.56
52 Week Range66.00 - 97.98
Volume3,870,994
Avg. Volume4,850,750
Net Assets4.95B
NAV93.33
PE Ratio (TTM)N/A
Yield0.22%
YTD Return10.02%
Beta (3y)1.78
Expense Ratio (net)0.35%
Inception Date2006-01-31
Trade prices are not sourced from all markets
  • Turbulence ahead? Two trades to make
    CNBC Videos23 days ago

    Turbulence ahead? Two trades to make

    On a day when the Dow's record high would normally be the top story, two 'Fast Money' traders discuss Wynn shares and what they bought Friday.

  • Best bets for growth at record highs
    CNBC Videos26 days ago

    Best bets for growth at record highs

    Biotech and tech surge. What to buy in a raging rally, with CNBC's Melissa Lee and the Fast Money traders.

  • Apple, Boeing Soar As Market Rallies; Bitcoin Ignores Warning
    Investor's Business Daily6 days ago

    Apple, Boeing Soar As Market Rallies; Bitcoin Ignores Warning

    Key market index funds extended their gains Monday as Apple and Boeing led the Dow Jones industrial average.

  • Investopedia11 days ago

    Biotech Stocks Trade Near Major Levels of Support

    With biotech stocks tumbling toward long-term levels of support, we take a closer look at how active traders will trade the bounce.

  • ETF Trends13 days ago

    Healthcare Dip Could be a Buying Opportunity

    The Health Care Select Sector SPDR (NYSEArca: XLV), the largest exchange traded fund dedicated to the S&P 500’s third-largest sector weight, tumbled last week, but some market observers believe the decline ...

  • 3 Ways to Profit from the Market Panic
    InvestorPlace13 days ago

    3 Ways to Profit from the Market Panic

    Panic is in the air; fear is on the rise. And that smug grin on bulls’ faces following such an epic start to 2018 is beginning to turn. Friday’s 2.54% drubbing in the Dow Jones Industrial Average has left many investors shell-shocked.

  • Why the Physician Office Pain Management Market Matters to MiMedx
    Market Realist13 days ago

    Why the Physician Office Pain Management Market Matters to MiMedx

    Why Investors Are Eyeing MiMedx Group Today

  • Comparing Cara Therapeutics’ Financial Performance
    Market Realist16 days ago

    Comparing Cara Therapeutics’ Financial Performance

    What's in Store for Cara Therapeutics in 2018?

  • MarketWatch17 days ago

    Pharmaceutical stocks drop after drug price mention in Trump’s State of the Union

    Trump described drug prices as “one of my greatest priorities,” but his administration has released nothing in the way of policy over the last year.

  • Analyst Ratings for Array BioPharma and Peers in January 2018
    Market Realist19 days ago

    Analyst Ratings for Array BioPharma and Peers in January 2018

    Array BioPharma (ARRY) is a biopharmaceutical company focused on discovery, development, and commercialization of small molecule drugs for the treatment of patients suffering from cancer. Of the nine analysts covering Array BioPharma (ARRY) in January 2018, eight have given the stock a “buy” or higher rating, and one has given it a “hold.” The mean rating for the stock is 1.78 with a target price of $16.22. Array BioPharma makes up 1.9% of the SPDR S&P Biotech ETF’s (XBI) total portfolio holdings.

  • Biotech ETF (XBI) Hits New 52-Week High
    Zacks19 days ago

    Biotech ETF (XBI) Hits New 52-Week High

    This biotech ETF hit a new 52-week high. Are more gains in store for this fund?

  • MarketWatch20 days ago

    Not even Solid Biosciences’ latest disclosure could sour its market debut

    The company revealed on Thursday a partial clinical hold on its lead product dating back to November.

  • Investopedia23 days ago

    Top 3 Healthcare ETFs for 2018

    The solid performance of the healthcare market in 2017 has created investment opportunities. These ETFs are poised to take advantage.

  • A Strong Pipeline of Drugs Bodes Well for Radius Health
    Market Realist24 days ago

    A Strong Pipeline of Drugs Bodes Well for Radius Health

    The drug candidates in Radius Health’s (RDUS) pipeline include an investigational abaloparatide transdermal patch for possible use in treating women with postmenopausal osteoporosis. Another candidate is the investigational drug elacestrant (or RAD1901), which is a selective estrogen receptor degrader for the treatment of hormone receptor-positive breast cancer and the treatment of vasometer symptoms in postmenopausal women. The pipeline also includes the investigational drug RAD140, a nonsteroidal selective androgen receptor modulator, for its potential use in treating hormone receptor-positive breast cancer.

  • Investopedia26 days ago

    Biotech M&A Spree Could Push Sector to New Record Highs

    Biotech shares surged on Monday following news of big M&A activity.

  • ETF Trends27 days ago

    Biotech ETFs Pop on Celgene, Juno Deal

    This article was originally published on ETF Trends.com. Biotechnology sector-related ETFs surged Monday after Celgene (NasdaqGS: CELG) said it will acquire Juno Therapeutics (NasdaqGS: JUNO) to expand ...

  • MarketWatch27 days ago

    Biotech ETF rallies on merger news, on track for highest close since 2015

    The largest exchange-traded fund to track the biotechnology sector rallied on Monday, supported by a pair of multibillion-dollar deals. The iShares Nasdaq Biotechnology ETF jumped 1.8%. At current levels, ...

  • Barrons.comlast month

    Overriding the Windfall? Why Boring Is in Biotech's Earnings Future

    Biotech stocks face a challenging 2018. Large companies are feeling pressed to do growth-spurring deals while the rally in smaller firms has pushed up their prices. And then there are the management teams ...

  • Best ETFs for 2018: The SPDR S&P Biotech ETF (XBI) Will Continue to Rock
    InvestorPlacelast month

    Best ETFs for 2018: The SPDR S&P Biotech ETF (XBI) Will Continue to Rock

    This article is a part of InvestorPlace’s Best ETFs for 2018 contest. Johnson Research Group’s pick for the contest is the SPDR S&P Biotech (ETF) (NYSEARCA:XBI). 2018 has gotten off to a roaring start, and biotechnology stocks are no exception.

  • Investopedialast month

    Biotech Stocks Near Massive Breakout

    Biotechnology stocks could score huge wins as a potentially historic sector breakout lurks on the horizon.

  • How Is Bioverativ’s Alprolix Positioned Now?
    Market Realistlast month

    How Is Bioverativ’s Alprolix Positioned Now?

    In 3Q17, Bioverativ’s (BIVV) drug Alprolix generated revenue of $88.5 million, which reflected a rise of ~4% on a year-over-year (or YoY) basis. In 3Q17, Alprolix contributed ~32.2% of Bioverativ’s net product sales. Alprolix reported revenue of $264.2 million in the first nine months of 2017 (which ended in September 2017) compared to its revenue of $240.5 million in the first nine months of 2016.

  • How Ionis’s Spinraza Performed in 3Q17
    Market Realistlast month

    How Ionis’s Spinraza Performed in 3Q17

    What's the Word on Ionis Pharmaceuticals This January?

  • Analysts’ Recommendations for Incyte in January 2018
    Market Realistlast month

    Analysts’ Recommendations for Incyte in January 2018

    As we discussed earlier, Incyte (INCY) reported a 41.6% rise in its revenue to $381.5 million in 3Q17. Further, Wall Street analysts expect a 26.7% rise in Incyte’s revenue to $413.8 million in 4Q17 and a 35.9% rise in its revenue to $1.5 billion for the entirety of 2017. Incyte’s stock price has fallen nearly 4.3% over the last 12 months and nearly 3.9% year-to-date in 2018.

  • Analyst Recommendations for Ignyta and Its Peers in January 2018
    Market Realistlast month

    Analyst Recommendations for Ignyta and Its Peers in January 2018

    Delaware-based Ignyta (RXDX) is focused on precision medicine in oncology. It endeavors to eradicate residual disease or the source of a reoccurrence of cancer in targeted patient populations. Ignyta is pursuing an integrated therapeutic and diagnostic strategy to treat cancer patients.

  • 3 Sector ETFs for 2018
    Zackslast month

    3 Sector ETFs for 2018

    Inside three sector ETFs that could prove to be good picks for this year.